Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer
Cells · 2024
DOI: 10.3390/cells13110957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Chaitanya K Valiveti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA. Hauptthemen laut MEDLINE: Curcumin, Colorectal Neoplasms, Colitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, NIH HHS.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic gut disorder that also elevates the risk of colorectal cancer (CRC). The global incidence and severity of IBD are rising, yet existing therapies often lead to severe side effects. Curcumin offers potent anti-inflammatory and chemotherapeutic properties. However, its clinical translation is hindered by rapid metabolism, as well as poor water solubility and stability, which limits its bioavailability. To address these challenges, we developed OC-S, a water-soluble and colon-targeted curcumin formulation that protects against colitis in mice. The current study advances OC-S as a dietary supplement by establishing its stability and compatibility with various commercial dietary products. Further, OC-S exhibited specific binding to inflamed colon tissue, potentially aiding in targeted drug retention at the inflammation site in colitis with diarrhea symptoms. We further investigated its efficacy in vivo and in vitro using a murine model of colitis and tumoroids from APCmin mice. OC-S significantly reduced colitis severity and pro-inflammatory cytokine expression compared with curcumin, even at very low doses (5 mg/kg/day). It also demonstrated higher anti-proliferative activity in CRC cells and colon cancer tumoroids vs. curcumin. Overall, this study demonstrated that OC-S effectively targets and retains water-soluble curcumin at the inflamed colon sites, while showing promise in addressing both colitis and colorectal cancer, which potentially paves the way for OC-S to advance into clinical development as a dietary product for both IBD and CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA.
ORCID-Profile: Balawant Kumar, Rizwan Ahmad
Förderung
- NIDDK NIH HHS
- BLRD VA
- NIH HHS
- VA-merit award
- NIH-1R15DK125940-01A1
- Haarberg 3D center
- National Institute of Health
Zitieren
APA
Valiveti, C. K., Kumar, B., Singh, A. D., Biradar, S. K., Ahmad, R., Singh, A. B., & Tummala, H. (2024). Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer. Cells. https://doi.org/10.3390/cells13110957
Vancouver
Valiveti CK, Kumar B, Singh AD, Biradar SK, Ahmad R, Singh AB, et al. Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer. Cells. 2024. doi:10.3390/cells13110957
BibTeX
@article{Valiveti2024,
author = {Valiveti, Chaitanya K and Kumar, Balawant and Singh, Anuj D and Biradar, Sham K and Ahmad, Rizwan and Singh, Amar B and Tummala, Hemachand},
title = {Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13110957}
}
EUVIMED